EU Pharma Loses €10.2bn, 38,000 Jobs To Counterfeits As “Massive” Track & Trace Obligations Approach
As a new report reveals that 4.4% of legitimate sales of drugs are lost each year in the EU due to counterfeiting, drug companies are being warned not to underestimate how much work they will need to do to comply with new track and trace rules.
You may also be interested in...
New Irish system will link into the European verification network that is being set up to detect incidents of falsified medicines entering the supply chain using a "unique identifier" on most packs of prescription drugs, starting from February 2019.
The new EU rules on the safety feature to be attached to almost all prescription medicines have finally been published, and once they kick in products will have to carry a 'unique identifier' in the form of a 2D bar code on the pack that will allow its authenticity to be verified1.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.